ESR1 and breast carcinoma: The inclusion of ER-negative cell lines (e.g., BT-549, MDA-MB-231, MDA-MB-453) in our study, despite the focus on ER+ breast cancer, was intended to validate AR responsiveness to DHT across subtypes (Figure 1A).